Efficacy of Diabetinol™ on glycemic control in insulin resistant hamsters and subjects with impaired fasting glucose - a pilot study

Journal of Functional Foods

Volumn 2, Issue 3, 2010, Pages 171-178

  Judy, William ^a   Stogsdill, Willis ^a   Judy, Daniel ^a   Judy, Janet ^a   Sharma, Prachi ^b   Evans, Malkanthi ^b   Guthrie, Najla ^b  

^a SIBR Research Inc   (United States)

^b KGK Synergize Inc   (Canada)

Author keywords

Diabetinol ; Glucose intolerance; HbA1c; Impaired fasting glucose; LDL cholesterol

Indexed keywords

ANIMALIA; CRICETINAE; MESOCRICETUS AURATUS;

EID: 77955664201     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2010.04.005     Document Type: Article

References (34)

1. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 2008, 358(24):2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
2. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008, 358(24):2560-2572. ADVANCE Collaborative Group.
3. American Diabetes Association (2008). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 31, S55-S60.
4. Anderson R.A., Polansky M.M. Tea enhances insulin activity. Journal of Agricultural and Food Chemistry 2002, 50:7182-7186.
5. Borradaile N.M., Caroll K.K., Kurowska E.M. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavones hesperetin and naringenin. Lipids 1999, 34:591-598.
6. Canadian Diabetes Association Clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008, 32(Suppl. 1).
7. Hermansen K., Sonder M., Hoie L., Carstensen M., Brock B. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 2001, 24:228-233.
8. Jayagopal V., Albertazzi P., Kilpatrick E.S., Howarth E.M., Jennings P.E., Hepburn D.A., et al. Beneficial effects of soy phyto estrogen intake in postmenopausal women with type II diabetes. Diabetes Care 2002, 25:1709-1714.
9. Knowler W.C., Barrett-Connor E., Flower S.E., et al. Reduction in the incidence of type II diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002, 346(6):393-403.
10. Kurowska, E. M., & Guthrie, N. (2003). Therapeutic potential of citrus flavonoids and tocotrienols, alone and in combinations, in hamsters with fructose-induced insulin resistance. 46th CFBS annual meeting. ON, Canada: Ottawa.
11. Kurowska, E. M., Casaschi, A., & Thiault, A. (2003). A flavonoid tangeretin modulates metabolism of hepatic lipids and apo-B containing lipoproteins through multiple mechanisms. Second congress, international academy nutrition and aging, Albuquerque: NM.
12. Kurowska E.M., Guthrie N., Manthey J.A. Hypolipidemic activities of tangeretin, a flavonoid from tangerines, in vitro and in vivo. FASEB Journal 2001, 15:A395.
13. Kurowska E.M., Manthey J.A. Regulation of lipoprotein metabolism in HepG2 cells by citrus flavonoids. Advances in Experimental and Medical Biology 2002, 505:173-179.
14. Kurowska E.M., Manthey J.A. Hypolipidemic effects and absorption of citrus polymethoxylated flavones in hamsters with diet-induced hypercholesterolemia. Journal of Agricultural and Food Chemistry 2004, 52:2879-2886.
15. Kurowska E.M., Manthey J.A., Casaschi A., Theriault A.G. Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin. Lipids 2004, 39:143-151.
16. LeRoith D. Hyperglycemia, hypertension, and dyslipidemia in type 2 diabetes mellitus: Goals for diabetes management. Clinical Cornerstone 2008, 9(2):S8-S16.
17. Li R.W., Theriault A.G., Au K., Douglas T.D., Casaschi A., Kurowska E.M., et al. Citrus polymethoxylated falvones improve lipid and glucose homeostasis and modulate adipocytokines in fructose-induced insulin resistant hamsters. Life Sciences 2006, 79:365-373.
18. Lipscombe L.L. Thiazolidinediones: Do harms outweigh benefits?. Canadian Medical Association Journal 2009, 180(1):16-17.
19. Mannucci E., Ognibene A., Sposato I., Brogi M., Gallori G., Bardini G., et al. Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetologica 2003, 40:181-186.
20. Moller D.E. New drug targets for type II diabetes and metabolic syndrome. Nature 2001, 414:821-827.
21. Nahas R., Moher M. Complementary and alternative medicine for the treatment of type 2 diabetes. Canadian Family Physician 2009, 55:591-596.
22. Rao A.D., Kuhadiya N., Reynolds K., Fonseca V.A. Is the combination of sulfonylureas and metformin associated with an increased cardiovascular disease or all cause mortality? A meta-analysis of observational studies. Diabetes Care 2008, 31(8):1672-1678.
23. Stevens R.J., Kothari V., Adler A.L., Stratton I.M. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clinical Science (London) 2001, 10(6):671-679. United Kingdom Prospective Diabetes Study (UKPDS) Group.
24. Taghibiglou C., Carpentier A., Van Iderstine S.C., Chen B., Rudy D., Aiton A., et al. Mechanism of hepatic very low density lipoprotein overproduction in insulin resistance. Journal of Biological Chemistry 2000, 275:8416-8425.
25. Tuomilehto J., Lindstorm J., Eriksson J.G., Valle T.T., Hamalainen H., IlanneParikka P., et al. Prevention of type II diabetes mellitus by changes in lifestyle amongst individuals with impaired glucose tolerance. New England Journal of Medicine 2001, 344(18):1343-1350.
26. Van Dam R.M., Feskens E.J. Coffee consumption and risk of type II diabetes mellitus. Lancet 2002, 360:1477-1478.
27. Vuksan V., Sievenpiper J.L., Koo V.Y., Francis T., Beljan-Zdravkovic U., Xu Z., et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type II diabetes mellitus. Archives of Internal Medicine 2000, 160:1009-1013.
28. Vuksan V., Sievenpiper J.L., Wong J., Xu Z., Beljan-Zdravkovic U., Arnason J.T., et al. American ginseng (Panax quinquefolius L.) attenuates postprandial glycemia in a time-dependent but not dose-dependent manner in healthy individuals. American Journal of Clinical Nutrition 2001, 73:753-758.
29. Vuksan V., Stavro M.P., Sievenpiper J.L., Beljan-Zdravkovic U., Leiter L.A., Josse R.G., et al. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type II diabetes. Diabetes Care 2000, 23:1221-1226.
30. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocrine Reviews 2007, 28(2):187-218.
31. Whitman S.C., Kurowska E.M., Manthey J.A., Daugherty A. Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages. Atherosclerosis 2005, 178:25-32.
32. World Health Organization (2006). Controlling the global obesity epidemic. WHO. http://www.who.int/nutrition/topics/obesity/en/.
33. Wu H.I. A case study of type 2 diabetes self-management. Biomedical Engineering (Online) 2005, 4(4):4.
34. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.